Trilaciclib plus chemotherapy before surgery for triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests whether adding trilaciclib to standard chemotherapy before surgery can improve outcomes for people with triple-negative breast cancer. It’s for patients who are starting treatment for the first time and can safely receive pre-surgery chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and starting treatment for breast cancer for the first time
- Your breast tumor is invasive cancer and has not spread to distant organs (no metastasis)
- Your tumor is triple-negative: estrogen- and progesterone-receptor negative and HER2 negative
- Your health and blood counts are strong enough for chemotherapy (key lab levels must meet minimums)
- You have not had certain growth-factor or related medications (like G-CSF) in the 2 weeks before screening
- You can safely have chemotherapy and, if you can get pregnant, you agree to effective birth control for the study and after
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding trilaciclib to standard chemotherapy after surgery can help people with hormone receptor-negative breast cancer. It aims to reduce side effects and improve treatment outcomes.
This trial tests a new drug combination for people with locally advanced triple-negative breast cancer who haven't had treatment yet. The goal is to see if adding trilaciclib to standard chemo and immunotherapy works better before surgery.
This trial tests whether adding trilaciclib to the chemotherapy drug eribulin can protect bone marrow and improve outcomes in people with advanced triple-negative breast cancer who have already tried at least two other chemotherapies.
This trial tests if trilaciclib can protect bone marrow during chemoradiation after surgery for advanced head and neck cancer. It is for people with specific risk factors found after surgery.
This trial tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy (carboplatin + paclitaxel) before surgery can improve outcomes for people with early-stage triple-negative breast cancer. It aims to shrink the tumor and increase the chance of a complete response.
This trial tests if adding the immunotherapy drug camrelizumab to standard chemotherapy before surgery can improve outcomes for women with early or locally advanced triple-negative breast cancer. It is for those who haven't had treatment yet and are candidates for surgery.
Hear when a new Breast Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.